Single center experience in patients with a diagnosis of nodular lymphocyte predominant Hodgkin lymphoma

Authors : Ömer CANDAR, Fahir ÖZKALEMKAŞ, Vildan OZKOCAMAN, Tuba ERSAL, İbrahim Ethem PINAR, Cumali YALÇIN, Bedrettin ORHAN

Pages : 40-41

Doi:10.46310/tjim.877049

View : 43 | Download : 20

Publication Date : 2021-03-07

Article Type : Other Papers

Abstract :Nodular lymphocyte predominant Hodgkin lymphoma is an infrequent disease. It is associated with a favorable prognosis. The most important problems with the management of the disease are relapses, transformation to non-Hodgkin lymphoma, and treatment-related toxicities. In early stages of disease, watchful waiting, surgery, radiotherapy, and single-agent rituximab are the treatment options. Chemo-immunotherapy may be preferred in early disease with high tumor and symptom burden. In advanced disease, chemo-immunotherapy with or without radiotherapy is used. Good responses can be achieved in relapsed disease. The risk of transformation is high. It is reasonable to obtain re-biopsies at relapses. Transformed disease and the primary disease have been shown to be clonally-related in most cases. Prognosis of transformed disease which is treated with salvage chemo-immunotherapy followed by autologous stem cell transplantation is similar to that of de novo diffuse large B-cell lymphoma. All of the data regarding the treatment come from retrospective data.
Keywords : Nodular lymphocyte predominant Hodgkin lymphoma, Hodgkin lymphoma, prognosis

ORIGINAL ARTICLE URL